Miltefosine Combined with Intralesional Pentamidine for Leishmania braziliensis Cutaneous Leishmaniasis in Bolivia

Am J Trop Med Hyg. 2018 Nov;99(5):1153-1155. doi: 10.4269/ajtmh.18-0183.

Abstract

Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 μg/mm2 lesion area on days 1, 3, and 5). Ninety-two per cent of 50 patients cured. Comparison to historic controls at our site suggests that the efficacy of the two drugs was additive. Adverse effects and cost were also additive. This combination may be attractive when a prime consideration is efficacy (e.g., in rescue therapy), avoidance of parenteral therapy, or the desire to treat locally and also provide systemic protection against parasite dissemination.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiprotozoal Agents / administration & dosage
  • Antiprotozoal Agents / economics
  • Antiprotozoal Agents / therapeutic use*
  • Bolivia
  • Drug Therapy, Combination / adverse effects
  • Drug Therapy, Combination / economics
  • Female
  • Humans
  • Leishmania / drug effects*
  • Leishmania braziliensis / drug effects*
  • Leishmaniasis, Cutaneous / drug therapy*
  • Male
  • Pentamidine / administration & dosage
  • Pentamidine / adverse effects
  • Pentamidine / economics
  • Pentamidine / therapeutic use*
  • Phosphorylcholine / administration & dosage
  • Phosphorylcholine / adverse effects
  • Phosphorylcholine / analogs & derivatives*
  • Phosphorylcholine / economics
  • Phosphorylcholine / therapeutic use
  • Treatment Outcome

Substances

  • Antiprotozoal Agents
  • Phosphorylcholine
  • miltefosine
  • Pentamidine